Board Directors
Prior to joining Biofortuna, Nick was CEO of Source BioScience plc, the Main Market-listed healthcare diagnostics and genomic services business, where he established operations in the US and Europe, growing revenues five fold.
Nick holds a PhD in Mycology and is a Chartered Accountant, qualifying with KPMG. Nick is also Chairman of Epistem Limited, the pre-clinical and clinical development CRO.
Prior to joining Biofortuna, Nick was COO of Source BioScience plc, expanding the laboratory infrastructure from a single site in the UK to ten facilities worldwide. Before Source BioScience, Nick worked for over ten years in complex genetics and genomics, initially at Oxford University and then for the MRC at the Wellcome Trust Sanger Centre, subsequently Geneservice.
Nick qualified as a microbiologist and worked in the NHS, completing a PhD on the molecular methods used to characterise outbreaks of bacterial meningitis.
Fiona started her career at Deloitte working in the Transaction Services team, where she trained as a Chartered Accountant, following which she worked in the Corporate Finance team at Manchester Airport Group before joining Foresight in 2021.
Fiona holds a degree in Economics with French from the University of Nottingham.
